ENDP Endo International plc

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Recent Analyst Ratings for Endo International plc

Date	Price Target	Rating	Analyst
5/6/2022	$3.00 → $1.00	Neutral → Underweight	Piper Sandler
3/9/2022	$11.00 → $6.00	Buy	Citigroup
3/2/2022	$5.00 → $3.00	Neutral	Piper Sandler
3/2/2022	$5.00 → $2.00	Equal-Weight → Underweight	Barclays
12/16/2021	$7.00 → $5.00	Equal-Weight	Barclays
8/31/2021	$10.00 → $3.00	Overweight → Neutral	Piper Sandler
8/9/2021	$6.00 → $5.00	Sector Perform	RBC Capital

See more ratings

Endo International plc

Peers

Recent Analyst Ratings for Endo International plc

Endo International plc Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Tursi James Patrick returned 280,373 units of 2015 Stock Incentive Plan Restricted Stock Units to the company, closing all direct ownership in the company

SEC Form 4: Barry Patrick A converted options into 16,957 units of Ordinary Shares and covered exercise/tax liability with 9,116 units of Ordinary Shares, increasing direct ownership by 5% to 169,711 units (withholding tax)

SEC Form 4: Raciti Frank B. covered exercise/tax liability with 965 units of Ordinary Shares, decreasing direct ownership by 10% to 8,821 units to cover taxes

SEC Form 4: Maletta Matthew Joseph converted options into 34,414 units of Ordinary Shares and covered exercise/tax liability with 18,651 units of Ordinary Shares, increasing direct ownership by 5% to 351,085 units to cover withholding tax

SEC Form 4: Bradley Mark T. covered exercise/tax liability with 5,601 units of Ordinary Shares and converted options into 10,735 units of Ordinary Shares, increasing direct ownership by 5% to 101,477 units to satisfy withholding obligation

SEC Form 4: Coleman Blaise covered exercise/tax liability with 18,574 units of Ordinary Shares and converted options into 35,910 units of Ordinary Shares, increasing direct ownership by 4% to 422,066 units (tax withholding)

SEC Form 4: Barry Patrick A covered exercise/tax liability with 7,853 units of Ordinary Shares, decreasing direct ownership by 5% to 147,757 units (withholding tax)

SEC Form 4: Raciti Frank B. covered exercise/tax liability with 394 units of Ordinary Shares, decreasing direct ownership by 5% to 6,927 units (for withholding tax)

SEC Form 4: Bradley Mark T. covered exercise/tax liability with 7,789 units of Ordinary Shares, decreasing direct ownership by 8% to 87,408 units (for tax liability)

SEC Form 4: Coleman Blaise covered exercise/tax liability with 31,886 units of Ordinary Shares, decreasing direct ownership by 8% to 374,843 units to cover withholding tax